CN101595099B - 晶体盐酸度洛西汀 - Google Patents

晶体盐酸度洛西汀 Download PDF

Info

Publication number
CN101595099B
CN101595099B CN2007800231697A CN200780023169A CN101595099B CN 101595099 B CN101595099 B CN 101595099B CN 2007800231697 A CN2007800231697 A CN 2007800231697A CN 200780023169 A CN200780023169 A CN 200780023169A CN 101595099 B CN101595099 B CN 101595099B
Authority
CN
China
Prior art keywords
duloxetine hydrochloride
crystalline duloxetine
solution
preparing crystalline
hydrochloride according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800231697A
Other languages
English (en)
Chinese (zh)
Other versions
CN101595099A (zh
Inventor
姜维平
贾春荣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHENHUAXI PHARMACEUTICAL CO Ltd CHONGQING
Arrow International Ltd
Original Assignee
SHENHUAXI PHARMACEUTICAL CO Ltd CHONGQING
Arrow International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHENHUAXI PHARMACEUTICAL CO Ltd CHONGQING, Arrow International Ltd filed Critical SHENHUAXI PHARMACEUTICAL CO Ltd CHONGQING
Publication of CN101595099A publication Critical patent/CN101595099A/zh
Application granted granted Critical
Publication of CN101595099B publication Critical patent/CN101595099B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
CN2007800231697A 2006-06-23 2007-06-21 晶体盐酸度洛西汀 Expired - Fee Related CN101595099B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0612508.2 2006-06-23
GBGB0612508.2A GB0612508D0 (en) 2006-06-23 2006-06-23 Crystalline duloxetine hydrochloride
PCT/GB2007/002317 WO2007148096A1 (en) 2006-06-23 2007-06-21 Crystalline duloxetine hydrochloride

Publications (2)

Publication Number Publication Date
CN101595099A CN101595099A (zh) 2009-12-02
CN101595099B true CN101595099B (zh) 2013-03-06

Family

ID=36803803

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800231697A Expired - Fee Related CN101595099B (zh) 2006-06-23 2007-06-21 晶体盐酸度洛西汀

Country Status (10)

Country Link
US (1) US7795454B2 (enExample)
EP (1) EP2035403A1 (enExample)
JP (1) JP5247687B2 (enExample)
CN (1) CN101595099B (enExample)
AU (1) AU2007262794B2 (enExample)
BR (1) BRPI0712454A2 (enExample)
CA (1) CA2655962A1 (enExample)
GB (1) GB0612508D0 (enExample)
NZ (1) NZ572918A (enExample)
WO (1) WO2007148096A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0612508D0 (en) 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
EP2107057A1 (en) * 2008-04-04 2009-10-07 Ranbaxy Laboratories Limited Process for the preparation of pure duloxetine hydrochloride
CZ304602B6 (cs) * 2009-09-02 2014-07-30 Zentiva, K. S. Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu)
CN103626735A (zh) * 2012-08-28 2014-03-12 石药集团中奇制药技术（石家庄）有限公司 一种盐酸度洛西汀晶型及其制备方法
JP6178817B2 (ja) * 2015-04-27 2017-08-09 株式会社豊田中央研究所 光輝性塗料組成物、光輝性樹脂膜、及び、積層塗膜
CN106265528A (zh) * 2015-05-12 2017-01-04 法德生技药品股份有限公司 制备药物凝集体的方法
SG11202106445RA (en) 2019-01-03 2021-07-29 Dna Script One pot synthesis of sets of oligonucleotides
CN113603673B (zh) * 2020-11-16 2024-08-06 上海中西三维药业有限公司 一种盐酸度洛西汀的晶型、其制备方法及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005108386A1 (en) * 2004-05-11 2005-11-17 Cipla Limited Crystalline forms of duloxetine free base
WO2006071868A2 (en) * 2004-12-23 2006-07-06 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
WO2006081515A2 (en) * 2005-01-27 2006-08-03 Teva Pharmaceutical Industries Ltd. Duloxetine hydrochloride polymorphs
EP1820800A1 (en) * 2006-02-17 2007-08-22 KRKA, tovarna zdravil, d.d., Novo mesto Crystalline forms of duloxetine hydrochloride and processes for their preparation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
US20050197503A1 (en) 2004-03-05 2005-09-08 Boehringer Ingelheim International Gmbh Process for the preparation of N-alkyl-N-methyl-3-hydroxy-3-(2-thienyl)-propylamines
WO2006027798A2 (en) 2004-08-05 2006-03-16 Sun Pharmaceutical Industries Limited A process for preparation of an antidepressant compound
CZ297560B6 (cs) 2004-10-26 2007-02-07 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu)
EP1812428A2 (en) 2004-11-19 2007-08-01 Teva Pharmaceutical Industries Ltd Zolmitriptan crystal forms
WO2006058121A1 (en) 2004-11-23 2006-06-01 Bristol-Myers Squibb Company Crystalline forms of 3'-tert-butyl-3'-n-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-n-debenzoyl-4-o-methoxycarbonyl-paclitaxel
WO2006099433A1 (en) 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Pure duloxetine hydrochloride
GB0612508D0 (en) 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005108386A1 (en) * 2004-05-11 2005-11-17 Cipla Limited Crystalline forms of duloxetine free base
WO2006071868A2 (en) * 2004-12-23 2006-07-06 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
WO2006081515A2 (en) * 2005-01-27 2006-08-03 Teva Pharmaceutical Industries Ltd. Duloxetine hydrochloride polymorphs
EP1820800A1 (en) * 2006-02-17 2007-08-22 KRKA, tovarna zdravil, d.d., Novo mesto Crystalline forms of duloxetine hydrochloride and processes for their preparation

Also Published As

Publication number Publication date
JP2009541290A (ja) 2009-11-26
BRPI0712454A2 (pt) 2012-10-02
GB0612508D0 (en) 2006-08-02
WO2007148096A1 (en) 2007-12-27
NZ572918A (en) 2011-12-22
AU2007262794A1 (en) 2007-12-27
US20080021090A1 (en) 2008-01-24
CA2655962A1 (en) 2007-12-27
AU2007262794B2 (en) 2012-04-12
CN101595099A (zh) 2009-12-02
US7795454B2 (en) 2010-09-14
JP5247687B2 (ja) 2013-07-24
EP2035403A1 (en) 2009-03-18

Similar Documents

Publication Publication Date Title
CN101595099B (zh) 晶体盐酸度洛西汀
TWI311990B (en) New compounds with therapeutic effect
CN101627026A (zh) 晶体盐酸度洛西汀
CN102458435A (zh) 认知衰退的抑制剂
CN101631783A (zh) 晶体盐酸度洛西汀
WO2008042755A2 (en) Inhibitors of cognitive decline
JP2009541292A5 (enExample)
EP2358369A1 (en) Process for the preparation of substantially optically pure repaglinide and precursors thereof
Hu et al. Resolutions of sibutramine with enantiopure tartaric acid derivatives: chiral discrimination mechanism
BRPI0607436B1 (pt) Base cristalina do composto trans-1-((1r,3s)-6-cloro-3-fenil-indan1-il)-3,3-dimetil-piperazina, sua composição farmacêutica, seus usos, seu método de preparação, método para fabricação do referido composto, bem como base livre do referido composto
CN103570639A (zh) 一种利奈唑胺的合成方法
WO2006090263A1 (en) Stable form i donepezil hydrochloride and process for its preparation and use in pharmaceutical compositions
JP2016222628A (ja) デュロキセチン塩酸塩の製造方法
EP2177221A1 (en) Process for the preparation of substantially optically pure Repaglinide and precursors thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130306

Termination date: 20140621

EXPY Termination of patent right or utility model